Levetiracetam Kent Pharma Uk

Levetiracetam, the active ingredient in Levetiracetam Kent Pharma Uk, is an anticonvulsant presented as an oral dosage form for oral use. It treats partial (focal) seizures, generalized tonic‑clonic seizures and myoclonic seizures in patients with epilepsy.

GNH USA supplies Levetiracetam Kent Pharma Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug that modulates neuronal excitability to control seizure activity.

Partial (focal) seizures: reduces the frequency and severity of focal seizure episodes. Generalized tonic‑clonic seizures: helps prevent convulsive episodes across both cerebral hemispheres. Myoclonic seizures: decreases the occurrence of sudden, brief muscle jerks.

Levetiracetam may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Fatigue or somnolence - Headache - Irritability or mood changes

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Blood dyscrasias (e.g., neutropenia, thrombocytopenia) - Suicidal thoughts or depressive episodes - Significant skin rash or hypersensitivity reactions

Before initiating therapy, consider patient‑specific factors and monitor for adverse events.

Renal impairment: dose adjustment may be required based on creatinine clearance. Hepatic impairment: use with caution and monitor liver function. Pregnancy: limited data; discuss potential risks with a healthcare professional. Concomitant CNS depressants: may increase sedation or dizziness. Mood changes: monitor for depression, anxiety, or suicidal ideation. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Levetiracetam can interact with several medicines, affecting its plasma concentration or enhancing side effects.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam levels, decreasing efficacy. - Phenobarbital: can lower levetiracetam concentrations. - Phenytoin: may decrease levetiracetam exposure.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels, requiring observation. - Other CNS depressants (e.g., benzodiazepines): enhanced sedation risk. - Alcohol: additive CNS depressant effects may occur.